Clinical Trials in Acute Lymphoblastic Leukaemia (ALL)


Target mechanism of investigative drug


Title of clinical trial






The aims of this trial are to see if changing the standard treatment for children and young people with ALL or LBL will reduce side effects and help stop their disease from coming back. People aged 1 – 24 years old are eligible.





This trial is looking at new combinations of treatment for acute lymphoblastic leukaemia (ALL). In particular, it is looking at treatments for adults between 25 and 65 years old who have recently been diagnosed with acute lymphoblastic leukaemia, and for people between 19 and 65 who have ALL with the Philadelphia chromosome.





The aim of this study is to find a standard treatment for ALL in adults over the age of 60. Researchers can then use this in the future as a comparison when looking at any new treatments in clinical trials.





A phase 1 (first in human) study to look at the effectiveness of UCART19 (genetically modified T-Cells) in patients with ALL which has not responded to treatment, or has returned after previous successful treatment.



This trial compares selumetinib and dexamethasone for patients diagnosed with ALL